<SEC-DOCUMENT>0001437749-24-017181.txt : 20240515
<SEC-HEADER>0001437749-24-017181.hdr.sgml : 20240515
<ACCEPTANCE-DATETIME>20240515211800
ACCESSION NUMBER:		0001437749-24-017181
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240513
FILED AS OF DATE:		20240515
DATE AS OF CHANGE:		20240515

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Calder Douglas W
		CENTRAL INDEX KEY:			0001510445
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36913
		FILM NUMBER:		24953355

	MAIL ADDRESS:	
		STREET 1:		324 S. HYDE PARK AVENUE
		STREET 2:		SUITE 350
		CITY:			TAMPA
		STATE:			FL
		ZIP:			33606

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ZEVRA THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001434647
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				205894398
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		1180 CELEBRATION BOULEVARD, SUITE 103
		CITY:			CELEBRATION
		STATE:			FL
		ZIP:			34747
		BUSINESS PHONE:		(321) 939-3416

	MAIL ADDRESS:	
		STREET 1:		1180 CELEBRATION BOULEVARD, SUITE 103
		CITY:			CELEBRATION
		STATE:			FL
		ZIP:			34747

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KEMPHARM, INC
		DATE OF NAME CHANGE:	20130530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KEMPHARM INC
		DATE OF NAME CHANGE:	20080507
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>rdgdoc.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-05-13</periodOfReport>

    <issuer>
        <issuerCik>0001434647</issuerCik>
        <issuerName>ZEVRA THERAPEUTICS, INC.</issuerName>
        <issuerTradingSymbol>ZVRA</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001510445</rptOwnerCik>
            <rptOwnerName>Calder Douglas W</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ZEVRA THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>1180 CELEBRATION BOULEVARD, SUITE 103</rptOwnerStreet2>
            <rptOwnerCity>CELEBRATION</rptOwnerCity>
            <rptOwnerState>FL</rptOwnerState>
            <rptOwnerZipCode>34747</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>4.89</value>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2024-05-13</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>39200</value>
                    <footnoteId id="F2"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <value>2034-05-12</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>39200</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>39200</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 13, 2024.</footnote>
        <footnote id="F2">This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's ninth amended and restated non-employee director compensation policy.</footnote>
        <footnote id="F3">One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Douglas W. Calder</signatureName>
        <signatureDate>2024-05-15</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
